Paul J Catalano

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program
    Paul J Catalano
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215 5450, USA
    Med Care 51:e9-15. 2013
  2. pmc GSTM1 and APE1 genotypes affect arsenic-induced oxidative stress: a repeated measures study
    Carrie V Breton
    Harvard School of Public Health, Dept of Environmental Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Environ Health 6:39. 2007
  3. pmc Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    BMC Cancer 11:354. 2011
  4. pmc Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group
    Harry H Yoon
    Mayo Clinic, Rochester, MN 55905, USA
    BMC Cancer 11:176. 2011
  5. pmc Patients' expectations about effects of chemotherapy for advanced cancer
    Jane C Weeks
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    N Engl J Med 367:1616-25. 2012
  6. doi request reprint Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy
    Danielle N Margalit
    Department of Radiation Oncology, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA, USA
    Ann Surg Oncol 20:811-8. 2013

Collaborators

  • Jane C Weeks
  • Mehra Golshan
  • Beth A Overmoyer
  • Paul L Nguyen
  • Deborah Schrag
  • Jennifer W Mack
  • Jeannette Lee
  • Katherine L Kahn
  • Danielle N Margalit
  • S Yousuf Zafar
  • Harry H Yoon
  • Carrie V Breton
  • Meera Sreedhara
  • Jane E Brock
  • Yu Hui Chen
  • Jay R Harris
  • Geoffrey Liu
  • Mona N Fouad
  • Mark Powell
  • Lawrence R Kleinberg
  • Jane T Kolimaga
  • Patricia A Ganz
  • Elizabeth A Montgomery
  • Stephen J Meltzer
  • Leah L Zullig
  • Michael K Gibson
  • Dawn Provenzale
  • Todd C Skaar
  • Al B Benson
  • Kathleen M Murphy
  • Steven M Offer
  • David H Abbott
  • Dee W West
  • Michael J Hafez
  • Arlene A Forastiere
  • Jennifer L Malin
  • John Z Ayanian
  • Xifeng Wu
  • Steven C Grambow
  • Robert Wallace
  • Santosh Philips
  • Molly L Kile
  • Elaine Hoffman
  • Golam Mahiuddin
  • Quazi Quamruzzaman
  • Mahmuder Rahman
  • David C Christiani

Detail Information

Publications6

  1. pmc Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program
    Paul J Catalano
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215 5450, USA
    Med Care 51:e9-15. 2013
    ..As CanCORS results will inform national policy, it is important to know how they generalize to the United States population with these cancers...
  2. pmc GSTM1 and APE1 genotypes affect arsenic-induced oxidative stress: a repeated measures study
    Carrie V Breton
    Harvard School of Public Health, Dept of Environmental Health, 665 Huntington Avenue, Boston, MA 02115, USA
    Environ Health 6:39. 2007
    ..Chronic arsenic exposure is associated with an increased risk of skin, bladder and lung cancers. Generation of oxidative stress may contribute to arsenic carcinogenesis...
  3. pmc Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    BMC Cancer 11:354. 2011
    ..We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment...
  4. pmc Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group
    Harry H Yoon
    Mayo Clinic, Rochester, MN 55905, USA
    BMC Cancer 11:176. 2011
    ..As a secondary aim, we investigated the rate of allelic imbalance between germline and tumor DNA...
  5. pmc Patients' expectations about effects of chemotherapy for advanced cancer
    Jane C Weeks
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    N Engl J Med 367:1616-25. 2012
    ..Chemotherapy for metastatic lung or colorectal cancer can prolong life by weeks or months and may provide palliation, but it is not curative...
  6. doi request reprint Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy
    Danielle N Margalit
    Department of Radiation Oncology, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA, USA
    Ann Surg Oncol 20:811-8. 2013
    ..We document the immunophenotype, incidence of axillary metastases, and rate of recurrence in a well-defined case series...